Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Bellet, Meritxell
• dc.contributor.author Ruiz, Ada
• dc.contributor.author de la Peña, Lorena
• dc.date.accessioned 2020-04-29T07:30:29Z
• dc.date.available 2020-04-29T07:30:29Z
• dc.date.issued 2019
• dc.description.abstract Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
• dc.format.mimetype application/pdf
• dc.identifier.citation Bellet M, Ahmad F, Villanueva R, Valdivia C, Palomino-Doza J, Ruiz A, et al. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication. Ther Adv Med Oncol. 2019 May 10; 11: 1-43. DOI: 10.1177/1758835919833867
• dc.identifier.doi http://dx.doi.org/10.1177/1758835919833867
• dc.identifier.issn 1758-8340
• dc.identifier.uri http://hdl.handle.net/10230/44366
• dc.language.iso eng
• dc.publisher SAGE Publications
• dc.rights Copyright © The Author(s), 2019. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://www.creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword CDK inhibitors
• dc.subject.keyword Breast cancer
• dc.subject.keyword Palbociclib
• dc.subject.keyword Ribociclib
• dc.title Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion